What is Modulus Discovery?
Modulus Discovery operates at the intersection of biology, computational simulation, and scalable operations to advance its small-molecule drug discovery programs. With offices in Tokyo and Boston, the company leverages its unique core biology insights and cutting-edge molecular simulation platform to efficiently develop potential treatments for unmet medical needs. Its therapeutic focus spans critical areas such as oncology, chronic inflammation and immune disorders, infectious diseases, and rare genetic conditions, positioning it as a key player in the biopharmaceutical innovation landscape.
How much funding has Modulus Discovery raised?
Modulus Discovery has raised a total of $53.1M across 3 funding rounds:
Series A
$7.2M
Series B
$25.5M
Series C
$20.4M
Series A (2018): $7.2M with participation from DBJ Capital, Fast Track Initiative, and PeptiDream
Series B (2020): $25.5M led by Essential Pharma, Fast Track Initiative, MEDI-FUTURE Inc, SMBC Venture Capital, Keio Innovation Initiative Inc, Mizuho Capital, JAFCO, Dai-ichi, Mobile Internet Capital Inc, SBI Investment Korea Co., Ltd., and Utokyo Innovation Platform Co. Ltd
Series C (2022): $20.4M supported by SBI Group, Green Coinvest Investment Limited Partnership, and Height Capital Management
Key Investors in Modulus Discovery
SBI Group
SBI Group is a diversified financial services group with a history dating back to 1981, known for its involvement in various sectors including film project construction and facilitating access to bidding opportunities within the entertainment industry. Their expertise extends to supporting clients in the dynamic film and entertainment sectors.
Height Capital Management
Height Capital is a privately owned financial planning and accounting firm that provides tailored financial solutions, including planning, accounting, investment advice, and business advisory services. They focus on a personalized approach to help individuals, families, and businesses optimize their financial strategies.
DBJ Capital
DBJ Capital Co., Ltd. is a corporate venture capital firm established in 2010 and based in Tokyo, Japan. It specializes in investing in seed-stage companies and provides equity investment as growth funds for venture-stage firms.
What's next for Modulus Discovery?
The substantial enterprise-level backing Modulus Discovery has garnered, particularly the recent strategic investment, signals a pivotal phase for the company. This capital infusion is expected to accelerate the advancement of its drug discovery pipeline, potentially enabling the progression of promising candidates through preclinical development and towards clinical trials. The company's integrated approach, combining biological expertise with advanced simulation technology, positions it to tackle complex diseases and deliver novel therapies to patients. Future growth will likely involve expanding its research capabilities, forging new collaborations, and potentially seeking further strategic partnerships to maximize the impact of its discoveries.
See full Modulus Discovery company page
